CUPR is trading at $7.05 (7% up) in after-hours, extending a sharp regular-session rally following a major regulatory milestone.
- The stock surged approximately 48% on June 30 after the company announced FDA 510(k) clearance for its Medifly Maggots wound-care therapy.
- The regulatory approval has triggered heavy momentum trading and significant price swings in recent sessions as investors digest the news.
- Shares continue to see strong buying interest as the market reacts to the commercial potential of the newly cleared therapy.